Focused On-demand Library for Cytochrome P450 26B1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NR63

UPID:

CP26B_HUMAN

Alternative names:

Cytochrome P450 26A2; Cytochrome P450 retinoic acid-inactivating 2; Retinoic acid-metabolizing cytochrome

Alternative UPACC:

Q9NR63; B2R8M7; B7Z2K6; B7Z2P4; B7Z3B8; E4W5W7; Q32MC0; Q53TW1; Q9NP41

Background:

Cytochrome P450 26B1, also known as Cytochrome P450 retinoic acid-inactivating 2, plays a pivotal role in the metabolism of retinoic acids, vital signaling molecules derived from vitamin A. It primarily hydroxylates all-trans-retinoic acid, regulating its homeostasis and signaling. This enzyme is crucial in germ cell development, skeletal patterning, ossification of bone, and the establishment of synovial joints.

Therapeutic significance:

Understanding the role of Cytochrome P450 26B1 could open doors to potential therapeutic strategies. Its involvement in Radiohumeral fusions with other skeletal and craniofacial anomalies highlights its significance in skeletal development and potential targets for intervention.